|

Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer

RECRUITINGSponsored by Jena University Hospital
Actively Recruiting
SponsorJena University Hospital
Started2026-04-01
Est. completion2027-09-30
Eligibility
Age18 Years – 120 Years
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06355050

Summary

In this prospective, multi-center cohort study, the tolerability and quality of life during ultrahypofractionated radiotherapy (RT) of early stage prostate cancer is surveyed at several institutions in Germany. Radiotherapy is delivered by an online-adaptive RT device (Varian Ethos), which is able to correct daily variations in anatomy and to adjust the irradiation plan accordingly. A digital patient questionnaire is used to asses quality of life longitudinally. Quality of life (QoL) and toxicity profiles will be correlated with planning parameters and compared to retrospective cohorts of patients who underwent normofractionated RT or moderately hypofractionated RT, respectively.

Eligibility

Age: 18 Years – 120 YearsSex: MALEHealthy volunteers accepted
Inclusion Criteria:

* no androgen deprivation therapy within the last 2 months prior to RT
* good performance status (Eastern Cooperative Oncology Group, ECOG, 0/1)
* no secondary malignancy

Conditions4

Adaptive RadiotherapyCancerProstate CancerQuality of Life

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.